Year of publication: 2020

SIRS 2020

KarXT (Xanomeline, a Muscarinic Agonist Plus Trospium, a Peripheral Muscarinic Antagonist) Is Superior to Placebo in Patients With Schizophrenia: Phase 2 Clinical Trial Results

ICSTM 2020

Site Ratings Versus Site-Independent Ratings of PANSS Interviews in a Schizophrenia Study

ECNP 2020

Phase 2 Trial Results of KarXT (Xanomeline + Trospium) in Patients With Schizophrenia: Superior Efficacy to Placebo Across Positive and Negative Symptoms and a Favorable Safety/Tolerability Profile

CNS 2020

Site Ratings Versus Site-Independent Ratings of PANSS Interviews in a Schizophrenia Study

ASCP 2020

KarXT (a New Mechanism Antipsychotic Based on Xanomeline), Is Superior to Placebo in Patients With Schizophrenia: Phase 2 Clinical Trial Results

ACNP 2020

Molecular Mechanism of Antipsychotic Xanomeline’s Selectivity at Muscarinic Receptors